This site uses cookies to ensure the best viewing experience for our readers.
Allergan Can Now Sell 9.8% Teva Stake

Allergan Can Now Sell 9.8% Teva Stake

Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended

Dror Reich | 11:34  03.08.2017

Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended.

More on this subject

In 2016 Teva bought Allergan’s generic arm Actavis, paying $33.4 billion in cash, and about 100,000,000 shares—a 9.8% stake in the company, then worth $5.3 billion.

Teva headqurters, Petah-Tikva Teva headqurters, Petah-Tikva Teva headqurters, Petah-Tikva

Plagued by a series of business missteps, Teva’s stock price has taken a 42% dive over the last twelve months, losing 15% since the beginning of 2017.

CEO Erez Vigodman left Teva last February, following the resignations of Teva’s CFO Eyal Desheh, and head of global generic operations, Sigurdur Olafsson.

With the loss of Teva’s share value, Allergan had to write off $2 billion dollars in reports published last May. The write-off tipped its bottom line to losses.

Allergan stated in its annual reports that Teva’s shares were a short-term investment, and the likelihood of it selling those shares once the lock-up expired was high.

The market was keeping its calm ahead of the expiration date, possibly because Teva shares are now trading low.

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS